Genaissance Begins Enrolling Patients for Haplotype Studies | GenomeWeb

NEW YORK, April 24 - Genaissance Pharmaceuticals said Tuesday it had begun enrolling patients for its clinical trials which will aim to correlate haplotypes with individuals’ reactions to particular drugs.

In its initial study, the company plans to enroll about 600 patients at 60 medical centers in the US to correlate patient haplotypes with the affects of cholesterol lowering drugs. The Statin Response Examined by Genetic HAP Study, or STRENGTH, will look at Lipitor, Zocor, Pravachol, and Baycol. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.